Jul. 30 at 1:09 PM
$IMNN As much as I have criticized IMNN CEO and her team on their performance for shareholders I have to counter and ask. Not a single person who lost big on Celsion has ever answered this question. If the treatment is useless, why did one of the best journals in the field publish their Phase 2, why are some of the smartest doctors signing up to be part of the trials (including one from MD Anderson (not the consulting company) who came out recently with positive things to say), and why did FDA review and approve it for a Phase 3? So far the answer has been that message board people and hedge funds know more than the researchers who are just all doing it for the money.
There has to be a valuation floor based on the science and product alone, that is in a phase 3. But shareholders absolutely need to demand more from this CEO whose pay package alone is now 20% of the market cap.
